1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION, FL
Zevra Therapeutics Stockholders Elect Douglas W. Calder and Corey Watton
Reports First Quarter 2026 Financial Results and Corporate Update
Material Contracts, End of Material Contract, Reg. FD
.2 Appoints Justin Renz as Chief Financial Officer
Timothy Sangiovanni Appointed Interim Principal Financial Officer
Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
Announces CFO Transition
Reports Third Quarter 2025 Financial Results and Corporate Update
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus Filed Pursuant to Rule 424(b)(2)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Contested Proxy Solicitation Materials
PRRN14A
Definitive Additional Information Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence